TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2077498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chloral hydrate and hydroxyzine (placebo control)
Study: 2077498
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (three doses)
Study: 6778329
Drug: Antihistamine-adrenergic combination
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-adrenergic combination (diphenhydramine and pseudoephedrine)
Study: 25541338
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid 1.5 g in povidone-iodine solution (group B)
Study: 25541338
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid 3.0 g in povidone-iodine solution (group C)
Study: 25541338
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution (control: group A)
Study: 19203565
Drug: Clarithromycin (CLR)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CLR) 500 mg oral dose (Group 1: Merck; Group 2: Klaricid)
Study: 17381500
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (twice daily)
Study: 8068588
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of metronidazole three times daily for 5 days
Study: 8068588
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of metronidazole twice daily for 5 days
Study: 31126306
Drug: Creatine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine and electrolyte formulated multi‐ingredient performance supplement (MIPS)
Study: 24495636
Drug: Pressure therapy
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure therapy (PT)
Study: 18632424
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg per day for nine days, starting 48 hours before CPB, with an additional dose of 40 mg one hour after surgery
Study: 3514224
Drug: N 10
Normalized name: DYN 101
DrugBank: DYN-101 (DB17921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N 10 mg six times daily
Study: 3514224
Drug: V 80
Normalized name: omidubicel-onlv 8000000 CELLS/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: V 80 mg three times daily
Study: 3514224
Drug: ISDN 10
Normalized name: ISDN 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 10 mg six times daily
Study: 3514224
Drug: N 20
Normalized name: Span 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: N 20 mg six times daily
Study: 3514224
Drug: V 120
Normalized name: VYALEV 120 MG / 2400 MG in 10 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: V 120 mg four times daily
Study: 3514224
Drug: ISDN 20
Normalized name: ISDN 20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 20 mg six times daily
Study: 3514224
Drug: N r
Normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N r 20 mg four times daily
Study: 3514224
Drug: V r
Normalized name: HIV receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: V r 120 mg three times daily
Study: 3514224
Drug: ISDN sr
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN sr 40 mg four times daily
Study: 26230902
Drug: PDX/GOS (formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDX/GOS (formula with 4 g/L of PDX/GOS)
Study: 22378725
Drug: Capsinoids (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (9 mg)
Study: 30567753
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX)
Study: 20125159
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) and high-dose cytarabine (HD-AraC)
Study: 17347177
Drug: Gentamicin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (7.5 mg/kg, intramuscular, once daily)
Study: 10584136
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg, day 1 to 5 and 29 to 33) during concurrent radio-chemotherapy with carboplatin (70 mg/m2, day 1 to 5 and 29 to 33)
Study: 1988577
Drug: FEC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 50 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 50 mg/m2)
Study: 1988577
Drug: FEC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 75 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2)
Study: 1988577
Drug: Epirubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin alone (75 mg/m2)
Study: 24515544
Drug: Cystoscopic onabotulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystoscopic onabotulinum toxin A injection and oral placebo medication
Study: 24515544
Drug: Cystoscopic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystoscopic placebo injection and active oral medication
Study: 12119202
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg per day)
Study: 9854759
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment of six ineffective exercises
Study: 2142237
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg toremifene daily for 7 days
Study: 2142237
Drug: 68 mg
Normalized name: pyrantel 68 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68 mg toremifene for 5 days
Study: 2142237
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tamoxifen for 5 days
Study: 31999175
Drug: Telephone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based intervention (4 weekly calls + 5 biweekly calls)
Study: 31274183
Drug: High-dose Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sandostatin LAR monotherapy (40 mg)
Study: 31274183
Drug: High-dose Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sandostatin LAR plus pegvisomant
Study: 31274183
Drug: High-dose Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sandostatin LAR plus cabergoline
Study: 31274183
Drug: High-dose Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sandostatin LAR monotherapy
Study: 31274183
Drug: High-dose Sandostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sandostatin LAR (all groups)
Study: 31274183
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including combinations)
Study: 27067612
Drug: Myofascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial therapy protocol (21 minutes)
Study: 24338522
Drug: Generic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic medication switches
Study: 24338522
Drug: Confusion due
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confusion due to medication changes
Study: 24338522
Drug: No problems
Approvals — FDA: no, EMA: no, PMDA: no
Description: No problems with medication changes
Study: 23166441
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly and twice daily
Study: 17553207
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously every 3 months
Study: 15541406
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vitamin E daily
Study: 15541406
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg aspirin daily
Study: 15541406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin E and low-dose aspirin
Study: 10945509
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride 0.1% ophthalmic solution
Study: 11558863
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 0.05% ophthalmic solution
Study: 9156269
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) vaccine at 6, 8 and 14 months after BMT (early group, n = 23)
Study: 9156269
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) vaccine at 18, 20 and 26 months after BMT (late group, n = 22)
Study: 9156269
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) vaccine (both groups)
Study: 9156269
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid (TT) vaccine (late group)
Study: 23322362
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg/d)
Study: 29024120
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg once/6 months)
Study: 27146000
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1.6104 CFU of WRSS1 vaccine
Study: 25608849
Drug: AG‐dieckol (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG‐dieckol (1500 mg per day)
Study: 21040534
Drug: Screening program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening program for Q fever with immediate analysis of blood samples for IgG and IgM antibodies using a cut-off level of 1:32.
Study: 9583341
Drug: Complete cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete cognitive-behavioral therapy (CT)
Study: 2539762
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 mg once daily
Study: 2539762
Drug: Quinapril 5
Normalized name: quinapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 5 mg once daily
Study: 2539762
Drug: Quinapril administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril administered once or twice daily
Study: 335790
Drug: L-tryptophan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (6 g daily) with unilateral ECT
Study: 24068631
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/day for 6 weeks)
Study: 24068631
Drug: ER-niacin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER-niacin (0.5 g/day for 3 weeks, then 1 g/day for 6 weeks)
Study: 21378388
Drug: Troponin I
Normalized name: Troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin I (TnI) assessment at 24 hours (> 6.6 μg/l)
Study: 15472216
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (6 mg/d) for 3 months
Study: 11721171
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (anthracycline-based) for TCRBCL patients
Study: 11721171
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (anthracycline-based) for DLBCL patients
Study: 31375440
Drug: 7.5mcg or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mcg or 15mcg of hemagglutinin (HA)/dose for children 6-35 months; 15mcg HA/dose for children 3-17 years, administered via intramuscular injection, two doses 21 days apart.
Study: 31375440
Drug: H3N2v vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2v vaccine
Study: 28124817
Drug: Once-weekly titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly titration of IDegLira (based on mean of 2 pre-breakfast PG readings)
Study: 28124817
Drug: Twice-weekly titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly titration of IDegLira (based on mean of 3 pre-breakfast PG readings)
Study: 26106626
Drug: 40 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg/d vitamin D3
Study: 26106626
Drug: 80 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg/d vitamin D3
Study: 19964412
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (STN DBS + medication)
Study: 19964412
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (mof-sof)
Study: 17242254
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (standardized 5-week course)
Study: 15494583
Drug: Standardized dose‐matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dose‐matched therapeutic exercises (DMTE)
Study: 11448094
Drug: Haloperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1 mg i.v.)
Study: 11448094
Drug: Chlorpromazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (100 mg p.o.)
Study: 11448094
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg p.o.)
Study: 11448094
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg p.o.)
Study: 9506206
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Gamimune N)
Study: 2463035
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) (Fragmin) 2500 anti-factor Xa units twice daily for 7 days
Study: 2463035
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (Macrodex) 500 ml twice during the day of operation, followed by a single infusion of 500 ml on the first and again on the third postoperative day
Study: 27285306
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal pills (CHP)
Study: 1345694
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (10 mcg/kg.min for 1 hour)
Study: 1345694
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus dobutamine (D+) for 9 consecutive days
Study: 1345694
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (D-)
Study: 3877290
Drug: Propofol ('Diprivan')
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol ('Diprivan') 1.5 mg/kg
Study: 12712780
Drug: Thiopentone 2
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 2 mg/kg
Study: 16093575
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg daily for eight weeks)
Study: 12814141
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (up to 3100 microg)
Study: 7648804
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg daily
Study: 15671606
Drug: Tirofiban +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban + Heparin (Group III)
Study: 15671606
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Group I)
Study: 7996404
Drug: Retained anterior
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retained anterior capsule flap
Study: 24212227
Drug: Recanalization (RC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recanalization (RC) with 20 G endodiathermy bipolar probe connected to a 7 W diathermy followed by bicanalicular intubation
Study: 21515812
Drug: Oral dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of [D(10)]phenanthrene (10 μg)
Study: 21515812
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of [D(10)]phenanthrene (10 μg)
Study: 8383688
Drug: Granisetron 160
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 160 micrograms/kg (additional doses allowed)
Study: 31957251
Drug: WBI/WBI-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBI/WBI-chemotherapy
Study: 31184015
Drug: Intravesical sodium
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical sodium hyaluronate 50 ml 1 time per week for 12 weeks
Study: 31184015
Drug: Intravesical sodium
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical sodium hyaluronate combined with oral chondroitin sulfate 0.39 g (2 capsules 3 times a day) for 12 weeks
Study: 1814902
Drug: Azoran (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azoran (1000 mg)
Study: 1814902
Drug: Imuran (imported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imuran (imported formulation)
Study: 17139602
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with endothelin-receptor inhibitors, phosphodiesterase-5 inhibitors, and prostanoids
Study: 17139602
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (e.g., Imatinib)
Study: 14663808
Drug: 4.8% tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8% tranexamic acid mouthwash (10 mL, 4 times a day for 7 days postoperatively)
Study: 8926685
Drug: Intense preradiation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense preradiation chemotherapy
Study: 1290924
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg/day for 4 days)
Study: 6585734
Drug: 3‐mg prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mg prostaglandin E2 vaginal suppository
Study: 26787238
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone
Study: 24711779
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of manual and manipulative therapy
Study: 15827075
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program in a community pharmacy
Study: 11574338
Drug: Balanced Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Fluid group (Hartmann's solution and 6% hetastarch in balanced electrolyte and glucose injection)
Study: 11574338
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (0.9% sodium chloride solution and 6% hetastarch in 0.9% sodium chloride solution)
Study: 9576119
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 or 20 mg BID
Study: 9576119
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 or 10 mg BID
Study: 8154647
Drug: Accelerated-dose tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-dose tissue plasminogen activator (tPA)
Study: 24252845
Drug: EPA+DHA supplementation
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA supplementation (0, 300, 600, 900, 1800 mg daily)
Study: 18981939
Drug: GLU +
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU + CAF (6.4% glucose plus caffeine providing 5.3 mg kg(‐1) of caffeine)
Study: 14634576
Drug: Presumptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment with azithromycin, cefixime, and metronidazole
Study: 14634576
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for Trichomonas vaginalis
Study: 9008498
Drug: Tolcapone 50
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone 50 mg tid
Study: 9008498
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg tid
Study: 9008498
Drug: Tolcapone 400
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone 400 mg tid
Study: 3297181
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three dosage regimens (RR, SR, SR-F)
Study: 23975663
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (oxaliplatin/FU) - Arm B
Study: 23975663
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction chemotherapy - Arm A
Study: 21439823
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m² IV on days 1, 8, 15, 22, and 29) and uracil-tegafur (300 mg/m² TID from days 1-28) with folinic acid (90 mg QD)
Study: 11743288
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose conformal radiation therapy (77.4 Gy delivered to the prostate)
Study: 9521253
Drug: L-deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl (10 mg daily)
Study: 2913547
Drug: Cefuroxime or
Normalized name: cefuroxime Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime or ceftriaxone therapy
Study: 27928721
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg selenium supplements as tablet (n = 30)
Study: 17267841
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment at 20-24 weeks